X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CBP-201 (rademikibart) is an IL-4 alpha receptor Inhibitor Antibody drug candidate, which is being evaluated for the treatment of Moderate-to-Severe Asthma.
Lead Product(s): Rademikibart
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
CBP-201 (rademikibart) is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). It is in development for the treatment of atopic dermatitis (AD) and asthma.
Lead Product(s): Rademikibart
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.
Lead Product(s): Rademikibart
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jiangsu Simcere Pharmaceutical
Deal Size: $141.0 million Upfront Cash: $21.0 million
Deal Type: Licensing Agreement November 21, 2023
Details:
CBP-201 (rademikibart) is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), and is in development in patients with moderate-to-severe atopic dermatitis (AD).
Lead Product(s): Rademikibart
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
CBP-201 (rademikibart) is an inhibitory human monoclonal antibody against the IL-4Rα. It is being evaluated in phase 3 clinical trials for the treatment of Atopic Dermatitis.
Lead Product(s): Rademikibart
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
CBP-307 (icanbelimod) is an once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).
Lead Product(s): S1p receptor agonist 1
Therapeutic Area: Gastroenterology Product Name: CBP-307
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), it is in development for the treatment of atopic dermatitis (AD) and asthma.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. As an inhibitor of IL-4Rα, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), a validated target for the treatment of several inflammatory diseases, including AD.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Primary endpoint of IGA of 0 or 1 with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001).
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
